Cephalon Sues Hetero Over Generic Leukemia Drug

Law360, New York (December 20, 2013, 3:25 PM EST) -- Cephalon Inc. filed suit in Delaware federal court Thursday alleging rival Hetero Labs Ltd.'s plans to manufacture a generic form of its cancer treatment Treanda violated a patent for the drug, the second infringement suit the Pennsylvania-based pharmaceuticals maker has brought over Treanda in two months.

Hetero's abbreviated new drug application to U.S. regulators seeking to market injectible bendamustine hydrochloride to treat chronic lymphocytic leukemia prior to the expiration of Cephalon's patents was unlawful, said the suit, asking the court to block the production of Hetero's...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.